Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.53
Industry P/E
--
Debt to Equity
--
ROE
-4.31 %
ROCE
-365.69 %
Div. Yield
0 %
Book Value
1.36
EPS
-15.04
CFO
$-135.77 Mln
EBITDA
$-213.41 Mln
Net Profit
$-123.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| -98.10 | -84.57 | -96.61 | -99.41 | -87.53 | -- | -- |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| -77.45 | 15.69 | -89.99 | -51.27 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9... inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306 Read more
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vincerx Pharma Inc (VINC) stood at $ 8 Mln as on 31-Dec-24
The share price of Vincerx Pharma Inc (VINC) is $0.10 (NASDAQ) as of 22-Apr-2025 16:29 EDT. Vincerx Pharma Inc (VINC) has given a return of -87.53% in the last 3 years.
Vincerx Pharma Inc (VINC) has a market capitalisation of $ 1 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Vincerx Pharma Inc (VINC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vincerx Pharma Inc (VINC) and enter the required number of quantities and click on buy to purchase the shares of Vincerx Pharma Inc (VINC).
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306
The CEO & director of Dr. Ahmed M. Hamdy M.D.. is Vincerx Pharma Inc (VINC), and CFO & Sr. VP is Dr. Ahmed M. Hamdy M.D..
There is no promoter pledging in Vincerx Pharma Inc (VINC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Vincerx Pharma Inc. (VINC) | Ratios |
|---|---|
|
Return on equity(%)
|
-431.29
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vincerx Pharma Inc (VINC) was $0 Mln.
$-0.03
(
